PMH6

IMPACT OF COMORBIDITIES ON ANTIDEPRESSANT INITIATION: DULOXETINE, VENLAFAXINE, AND ESCITALOPRAM VERSUS OTHER SSRIS
Liu X 1 , Chen Y 2 , Faries D 2 , Miner C 2 , Swindle R 1 1 Eli Lilly and Company, Indianapolis, IN, USA, 2 Lilly USA, LLC, Indianapolis, IN, USA OBJECTIVES: Although efficacy and safety are 2 key issues to be taken into account when choosing an antidepressant, many other factors may also influence treatment initiation. The purpose of the study was to examine the impact of comorbidities on the initiation of antidepressants: duloxetine (DLX), valenfaxine (VLX), and escitalopram (ECP) versus other SSRIs (OSSRI) in patients with major depressive disorder (MDD). METHODS: A total of 44,026 MDD patients from a large commercial administrative claims database were classified as initiators of DLX (n 7,567), VLX (n 6,106), ECP (n 10,239), or OSSRI (n 20,114) during the year 2006. Patients were classified on their first index medication during the study period. All patients had no active prescription of the same medication(s) in the prior 3 months. On the basis of ICD-9-CM, 17 systemic disease classes and 21 individual diseases in the prior 12 months were identified. RESULTS: Patients receiving DLX were more likely than those receiving VLX, ECP, and OSSRI to be female (75.1% vs. 71.5%, 69.7%, 70.5%, p 0.001) and aged 46 years or above (62.3% vs. 54.6%, 49.8%, 50.5%, p 0.001). Nearly all systemic disease classes and individual pain diseases were most prevalent in DLX patients, followed by VLX and ECP patients, with OSSRI patients being the least. Most significant predicting comorbid diseases (OR 1.40) of DLX initiation versus OSSRI were fibromyalgia (OR 1.86), low back pain (OR 1.54), and bipolar disorder (OR 1.43) after adjustment for demographics and other comorbidities. However, no comorbid diseases with an OR 1.40 were associated with VLX and ECP initiation versus OSSRI. CONCLUSIONS: Patients initiating DLX have the most comorbid diseases, followed by VLX, ECP, with patients initiating OSSRI having the least. Specifically, the presence of chronic pain diseases and bipolar disorder appear to be most significant predictors of DLX initiation relative to OSSRI. The objective of this analysis was to compare efficacy and safety of duloxetine with placebo in the treatment of major depressive disorder in Poland. METHODS: Comparison was based on a systematic review, carried out according to guidelines published by the Cochrane Collaboration and the Agency for Health Technology Assessment in Poland. The most important medical databases (MEDLINE, EMBASE, CENTRAL) were searched. Two reviewers independently had selected trials, assessed their quality and extracted data. For efficacy analysis improvements in Hamilton Rating Scale for Depression (HAM-D) and quality of life were measured. Percentage of patients responding to treatment (defined as 50% improvement in HAM-D) and percentage of patients achieving total remission (defined as 7 points HAM-D-17) were also reported. Head-to-head comparisons based on randomized controlled trials (RCTs) were performed both for safety and efficacy analysis. RESULTS: The results of 14 RCTs were included in the analysis. After 7 to 9 weeks of treatment duloxetine allowed better improvement than placebo in HAM-D scores (WMD 2.26 [ 2.94; 1.57] ) and in quality of life (WMD 3.60 [ 4.89; 2.31] . CONCLUSIONS: Duloxetine is efficacious drug in the treatment of patients with major depressive disorder. Safety profile seems to be acceptable (slightly worse than placebo).
PMH7 EFFICACY OF ANTIPSYCHOTICS IN THE PREVENTION OF
PMH9 A SYSTEMATIC REVIEW OF PHARMACOLOGICAL TREATMENTS FOR BIPOLAR I MANIA
Parkinson BT 1 , von Maltzahn R 2 1 AstraZeneca UK Ltd, Luton, Bedfordshire, UK, 2 AstraZeneca UK Ltd, Luton, UK OBJECTIVES: Update a previously published systematic review 1 of pharmacological treatments for acute mania in bipolar I disorder, to include recent publications, including new formulation quetiapine extended release (XR), and remission rates. METHODS: Systematic review of CENTRAL, EMBASE, MEDLINE, for randomised, controlled trials comparing placebo to: aripiprazole, carbamazepine, divalproex, haloperidol, lithium, olanzapine, quetiapine XR, and risperidone as monotherapy, in the treatment of acute mania in bipolar I disorder, published before March 2009. Trials of combination therapy and patients non-responsive to previous therapy were excluded. Data were combined through random effects meta-analyses using Comprehensive Meta Analysis. Summary effect estimates were presented as Relative Risk (RR) versus placebo and 95% Confidence Interval (95%CI). RESULTS: 408 publications were identified and overall 19 trials from 18 papers were included in the analysis. The results for remission reported that risperidone followed by quetiapine XR were the most effective antipsychotics: risperidone 
PMH10 EFFECTIVENESS AND COST-EFFECTIVENESS OF LIFESTYLE INTERVENTIONS IN PERSONS WITH SEVERE MENTAL DISORDERS. A SYSTEMATIC REVIEW
Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L Ghent University, Ghent, Belgium OBJECTIVES: When compared to the general population, people with severe When compared to the general population, people with severe mental disorder (SMD) more commonly show obesity, sedentary lifestyles and poor dietary choices. This review examines the effectiveness and cost-effectiveness of lifestyle interventions on physical activity and dietary choices in people with SMD. Included health outcomes were changes in weight, body mass index (BMI) and quality of life. METHODS: A systematic E-search strategy was conducted
A systematic E-search strategy was conducted using Medline, Web of Science and CINAHL to select articles of lifestyle interventions targeting exercise and dietary choices in people with SMD. In addition, the reference lists of retrieved articles from the E-databases were hand-searched.
RESULTS:
The search strategy produced 14 randomized and non-randomized comparative trials that met the inclusion criteria. Mean duration of the interventions was 20.0 10.84 weeks. Weight loss was reported in 11 studies, with a mean weight change of 1.96
1.84 kg in the intervention groups versus 1.77 2.12 kg in the control groups. kg in the control groups. kg in the control groups. Changes in BMI were 0.87 0.69 kg/m² and kg/m² and kg/m² and 0.64 0.96 kg/m² respectively in kg/m² respectively in kg/m² respectively in intervention and control groups. Differences in changes in weight and BMI between intervention and control groups were statistically significant in nine studies. The results also suggest that quality of life and general health could benefit from these kinds of interventions. For example, subjective improvements in quality of life (p 0.047) and in overall health (p 0.023) were found in the study of Evans et al. (2005) . In none of the studies, however, cost-effectiveness was examined. CONCLUSIONS: Small weight loss through lifestyle interventions targeting physical activity and dietary choices is possible in people with SMD. This is promising given the high prevalence of sedentary lifestyles and poor dietary choices and the effects of some atypical antipsychotics on weight gain. Further study of both effectiveness and costeffectiveness (including the most cost-effective 'dose') of lifestyle interventions in people with SMD is required.
PMH11 DIFFERENCES BETWEEN CHILDREN AND ADOLESCENTS IN TREATMENT RESPONSE TO ATOMOXETINE AND THE CORRELATION BETWEEN QOL AND ADHD CORE SYMPTOMS
Schacht A 1 , Escobar R 2 , Savill NC 3 , Wagner T 1 , Wehmeier PM 1 1 Lilly Deutschland GmbH, Bad Homburg, Germany, 2 Lilly Spain, Madrid, Spain, 3 Lilly UK, Basingstoke, UK OBJECTIVES: To explore differences between age subgroups in QOL in atomoxetine treated patients and evaluate correlations between ADHD core symptoms and QOL. METHODS: Pooled data of 5 similar clinical atomoxetine trials (8-12 weeks followup, 3 placebo-controlled, 2 open-label) were included in the analysis. All studies used the ADHD-RS and the CHIP-CE instruments. Treatment group differences (effect size vs. placebo) in CHIP-CE score changes were compared between different age groups ( /&GE;12YRS); RESULTS: A total of 611 children ( 12 yrs) and 183 adolescents ( 12 yrs) were included. Baseline CHIP-CE total t-scores (mean SD; norm: 50 10) were similar in children (29.3 11.58) and adolescents (27.5 12.29) (p 0.296). Greater impairments in the CHIP-CE 'achievement' domain were seen in adolescents than children (t-scores 31.0 10.26 and 28.9 10.71, respectively; p 0.05); there were no clinically relevant differences in other domains. For the CHIP-CE 'risk avoidance' domain, the effect size of atomoxetine was higher in adolescents than in children (0.83, p 0.001 and 0.37, p 0.005; age*treatment interaction p 0.059); age group differences for other domains and CHIP-CE total scores were not clinically relevant. ADHD-RS/CHIP-CE correlations were low at baseline but moderate for change from baseline being similar in age groups. Only the 'risk avoidance' domain showed a trend towards lower correlation of change in adolescents (r 0.384 and r 0.545). CONCLUSIONS: Both age groups showed a clinically relevant impairment of QoL at baseline which was similar for adolescents and children in four out of five CHIP-CE domains. In both groups, atomoxetine was effective in improving QoL. For the 'risk avoidance' domain, the effect size of atomoxetine was larger in adolescents than in children, while the ADHD-RS/CHIP-CE correlation was lower in adolescents, indicating a lower association with core symptoms.
PMH12 COMPARISON OF POLYPHARMACY VS MONOTHERAPY ON OCCURRENCE OF RELAPSE IN SCHIZOPHRENIC PATIENTS -ADVANTAGE OF PROPENSITY SCORING ADJUSTMENT
CREATIV-CEUTICAL, Paris, France, 2 CREATIV-CEUTICAL, PARIS, France, 3 University Claude Bernard Lyon I, Villeurbanne Cedex, France OBJECTIVES: The objective was to compare occurrence of relapse according to antipsychotic treatment (monotherapy vs polypharmacy), in a 2 year observational cohort of 288 French schizophrenic patients, using different methods of adjustment. METHODS: Relapse was defined by a usual, clinically well reproducible and validated definition. The occurrence of relapse between patients receiving one antipsychotic to patients receiving more than one antipsychotic was compared according to a Cox model including or not the propensity score (PS). The propensity score was calculated on socio-economic and demographic information, clinical variables, quality of life, medication information and attitude toward treatment. Cox models were built according to four usual methods to calculate the propensity score: 1-stepwise PS, continuous, 2-non stepwise PS, continuous, 3-non stepwise PS, quintiles 4-non stepwise PS quintiles used to stratify the sample. We also used standard adjustment using all variables included in the model estimating the PS. Likelihood, Akaike's information criterion (AIC) criterion and Schwatz's Bayesian Criterion (SBC) criterion were used to compare the models. RESULTS: The standard cox model reports significant decrease of relapse in patient receiving polytherapy. Consistently the four models based on propensity scoring methods did not find any difference between the two populations. The model that optimizes all criteria ( 2logL, AIC and SBC) is the model using the stratification on the propensity score. CONCLUSIONS: Polytherapy is not associated to a reduction of relapse while consistently literature reports major risk associated to polypharmacy including increased mortality. The use of propensity scoring is well established for observational data and this study illustrate that standard regression could be misleading.
PMH13 TIME TO OPTIMIZATION OF DOSE IN PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): DATA FROM THE NETHERLANDS
Sasane R, Hodgkins P Shire Pharmaceuticals, Wayne, PA, USA OBJECTIVES: To evaluate time to optimization of dose in children with ADHD in The Netherlands. METHODS: Claims data from the PHARMO medical record linkage system database from 48 geo-demographic areas in The Netherlands (2003) (2004) (2005) (2006) were analyzed from newly treated ADHD patients aged 6-17 years. Patients were followed for at least 12 months after treatment initiation with methylphenidate or atomoxetine. Demographic and medication characteristics at treatment initiation, and concurrent psychotropic treatments in the year before ADHD treatment initiation were recorded. For this analysis, only patients with ³5 dispensings for any ADHD drug during follow-up and no missing information on type of drug, strength, and number of pills per day were included. Optimized dosing regimen was defined as no change in type of drug, strength, and number of pills per day for 5 consecutive dispensings (no time restriction between dispensings). Time to optimized dosing regimen was defined as the number of days between the first dispensing for an ADHD drug (cohort entry date) and the first of five unchanged dispensings. RESULTS: Of 4909 children initiating treatment from 2003-2006, 3159 met selection criteria. The proportion of patients reaching dosing optimization with initial treatment was 69.8% for atomoxetine (ATX; n 37), 74.8% for short-acting methylphenidate (SA; n 2017), and 82.4% for long-acting methylphenidate (LA; n 262; P 0.05 for both ATX and SA vs LA). The median number of days required to reach optimal dosing regimen was 49 across the total sample. Among patients achieving dose optimization, those initiating treatment with LA had a significantly shorter time to dose optimization (14 days) than patients initially treated with SA (56 days; P 0.001) or ATX (31 days; P 0.05). CONCLUSIONS: Time to optimization of dosing regimen in children with ADHD in The Netherlands varied according to treatment chosen at initiation and was shortest for long-acting methylphenidate. Supported by funding from Shire Development Inc.
PMH14 ALZHEIMER'S DISEASE: A PHARMACOEPIDEMIOLOGICAL STUDY
Truter I Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa OBJECTIVES: Alzheimer's disease is an irreversible progressive disease that affects cognitive, behavioural and functional abilities. The prevalence of Alzheimer's disease is increasing as the world's population is aging. The primary aim of the study was to determine the prescribing patterns and cost of drugs for Alzheimer's disease in a private health care sector patient population. METHODS: A retrospective, exposurecohort pharmacoepidemiological study was conducted. Data were obtained from a South African private pharmacy group for 2008. The database consisted of 1,578,346 medicine records. RESULTS: A total of 588 patients (326 females and 262 males) received 2623 medicine items for Alzheimer's disease at a cost of R1,563,701.18 (average cost per item R596.15). The average age of patients was 75.54 (SD 10.48) years, with 78.40% of patients between 70 and 89 years of age. Donepezil was the most frequently prescribed active ingredient (37.09%), followed by galantamine (36.94%). Donepezil accounted for 39.50% of the cost of Alzheimer medication. No notable differences in prescribing patterns were observed over the 12-month period.
